Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound-guided local Remsima injection for complex perianal Crohn's disease
2019-000668-27Phase 2Active
- Sponsor
- Marta Maia Boscá Watts
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in Crohn's disease and anal fistula, sponsored by Marta Maia Boscá Watts. Primary endpoints: Combined remission at week 24 and Perianal disease clinical activity and morphology. Started Jul 2019; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2019-000668-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000668-27.